[go: up one dir, main page]

EE201300005A - Ravimkoostis - Google Patents

Ravimkoostis

Info

Publication number
EE201300005A
EE201300005A EEP201300005A EEP201300005A EE201300005A EE 201300005 A EE201300005 A EE 201300005A EE P201300005 A EEP201300005 A EE P201300005A EE P201300005 A EEP201300005 A EE P201300005A EE 201300005 A EE201300005 A EE 201300005A
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
EEP201300005A
Other languages
English (en)
Inventor
Iliich Epshtein Oleg
Alexandrovna Sergeeva Svetlana
Fyodorovna Dolgovyh Liudmila
Anatolievna Kheyfets Irina
Leonidovna Dugina Julia
Alexandrovna Zabolotneva Julia
Alexandrovich Tarasov Sergey
Original Assignee
Iliich Epshtein Oleg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE201300005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Iliich Epshtein Oleg filed Critical Iliich Epshtein Oleg
Publication of EE201300005A publication Critical patent/EE201300005A/et
Publication of EE05760B1 publication Critical patent/EE05760B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP201300005A 2010-07-15 2011-07-15 Ravimkoostis EE05760B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
PCT/IB2011/002404 WO2012007847A2 (en) 2010-07-15 2011-07-15 Pharmaceutical compositions and methods of treatment

Publications (2)

Publication Number Publication Date
EE201300005A true EE201300005A (et) 2013-08-15
EE05760B1 EE05760B1 (et) 2016-03-15

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP201300005A EE05760B1 (et) 2010-07-15 2011-07-15 Ravimkoostis

Country Status (30)

Country Link
US (1) US8865163B2 (et)
EP (1) EP2593477A2 (et)
JP (1) JP2013535436A (et)
KR (1) KR20140012009A (et)
CN (1) CN103124742A (et)
AR (1) AR082246A1 (et)
AU (1) AU2011278040B2 (et)
BR (1) BR112013000841A2 (et)
CA (1) CA2805091A1 (et)
CL (1) CL2013000098A1 (et)
CZ (1) CZ2013104A3 (et)
DE (1) DE112011102349T5 (et)
DK (1) DK201370078A (et)
EA (1) EA029400B1 (et)
EE (1) EE05760B1 (et)
ES (1) ES2542042R1 (et)
FI (1) FI20135146A7 (et)
FR (1) FR2962653A1 (et)
GB (1) GB2496076B (et)
IT (1) ITTO20110641A1 (et)
LT (1) LT5987B (et)
MX (1) MX361778B (et)
MY (1) MY158183A (et)
NO (1) NO20130219A1 (et)
NZ (1) NZ606768A (et)
PE (1) PE20131338A1 (et)
PH (1) PH12013500109A1 (et)
SE (1) SE1350179A1 (et)
SG (1) SG187037A1 (et)
WO (1) WO2012007847A2 (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CZ2013105A3 (cs) 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
ES2425314R1 (es) * 2010-07-15 2014-07-09 Oleg Iliich Epshtein Composición farmacéutica combinada y uso para preparar medicamentos destinados al tratamiento de trastornos del sistema genitourinario
JP2013532182A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
FR2962911A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter le trouble d'hyperactivite avec deficit de l'attention
KR20130103486A (ko) * 2010-07-21 2013-09-23 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
BR112013001296A2 (pt) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
WO2012017328A2 (en) * 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
US11421026B2 (en) * 2015-09-30 2022-08-23 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
PT4021505T (pt) * 2019-08-29 2024-03-11 Oleg Iliich Epshtein Medicamento para o tratamento de doenças infecciosas
CH721975A1 (de) * 2024-07-15 2026-01-30 Ilyich Epshtein Oleg Verfahren für den Erhalt von Kosmetik- und therapeutischen Kosmetikmitteln

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
UA32457C2 (uk) 1996-02-12 2000-12-15 Олєг Ільіч Епштейн Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
MX2008015621A (es) * 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
SG187035A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EP2596020A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
PH12013500143A1 (en) 2010-07-21 2019-09-02 Oleg Iliich Epshtein A method of treating alzheimer`s disease
FR2962911A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter le trouble d'hyperactivite avec deficit de l'attention
KR20130103486A (ko) 2010-07-21 2013-09-23 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
BR112013001296A2 (pt) 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa

Also Published As

Publication number Publication date
NZ606768A (en) 2015-08-28
MX361778B (es) 2018-12-17
MX2013000545A (es) 2013-10-28
CN103124742A (zh) 2013-05-29
EA201300133A1 (ru) 2014-03-31
CZ2013104A3 (cs) 2013-05-29
WO2012007847A2 (en) 2012-01-19
NO20130219A1 (no) 2013-03-22
MY158183A (en) 2016-09-15
AU2011278040A1 (en) 2013-03-07
BR112013000841A2 (pt) 2016-06-07
ES2542042R1 (es) 2015-10-06
AU2011278040B2 (en) 2016-06-02
SG187037A1 (en) 2013-02-28
JP2013535436A (ja) 2013-09-12
AR082246A1 (es) 2012-11-21
ITTO20110641A1 (it) 2012-01-16
GB2496076B (en) 2018-05-09
ES2542042A2 (es) 2015-07-29
LT2013015A (lt) 2013-11-25
FI20135146L (fi) 2013-02-15
PE20131338A1 (es) 2013-11-18
WO2012007847A3 (en) 2012-04-12
US8865163B2 (en) 2014-10-21
KR20140012009A (ko) 2014-01-29
CA2805091A1 (en) 2012-01-19
CL2013000098A1 (es) 2015-01-16
DE112011102349T5 (de) 2013-04-18
GB2496076A (en) 2013-05-01
GB201302653D0 (en) 2013-04-03
FR2962653A1 (fr) 2012-01-20
SE1350179A1 (sv) 2013-04-12
LT5987B (lt) 2014-01-27
FI20135146A7 (fi) 2013-02-15
EA029400B1 (ru) 2018-03-30
EP2593477A2 (en) 2013-05-22
PH12013500109A1 (en) 2015-07-03
DK201370078A (en) 2013-02-14
US20130017202A1 (en) 2013-01-17
EE05760B1 (et) 2016-03-15

Similar Documents

Publication Publication Date Title
SMT201700008B (it) Composizione farmaceutica
SMT201600350B (it) Composizioni farmaceutiche
DK3246018T3 (da) Farmaceutisk sammensætning
DK2694038T3 (da) Farmaceutisk sammensætning
DK3097925T3 (da) Farmaceutisk sammensætning
BR112012031667A2 (pt) composição
BRPI1004940A2 (pt) composição farmacêutica
BR112014003052A2 (pt) composições farmacêuticas
EE201300005A (et) Ravimkoostis
SMT201700095B (is) Composizioni farmaceutiche per inalazione
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
BRPI1012539A2 (pt) composições farmacêuticas
BR112012032683A2 (pt) composição
CO6930367A2 (es) Composiciones farmaceúticas
BRPI1015939A2 (pt) composição farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
HUE040370T2 (hu) Gyógyszerkészítmények
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
EP2628769A4 (en) FILM FORMING COMPOSITION
BR112012032980A2 (pt) composição
EP2635269A4 (en) COMBINATION COMPOSITION
CO6801722A2 (es) Composiciones farmacéuticas
EP2769718A4 (en) MEDICAL COMPOSITION

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20180715